38,829 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Bought by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. purchased a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 38,829 shares of the company's stock, valued at approximately $877,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Allspring Global Investments Holdings LLC raised its stake in shares of 10x Genomics by 113.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company's stock worth $26,000 after purchasing an additional 371 shares during the last quarter. Covestor Ltd lifted its stake in 10x Genomics by 501.7% during the 1st quarter. Covestor Ltd now owns 1,047 shares of the company's stock valued at $39,000 after acquiring an additional 873 shares in the last quarter. GAMMA Investing LLC boosted its holdings in 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock worth $35,000 after acquiring an additional 1,265 shares during the last quarter. Blue Trust Inc. boosted its holdings in 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock worth $40,000 after acquiring an additional 1,025 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of 10x Genomics in the 1st quarter worth $71,000. Institutional investors own 84.68% of the company's stock.

Insiders Place Their Bets

In related news, insider Benjamin J. Hindson sold 4,351 shares of the business's stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $98,028.03. Following the completion of the transaction, the insider now owns 345,704 shares of the company's stock, valued at approximately $7,788,711.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other 10x Genomics news, CFO Justin J. Mcanear sold 2,961 shares of the firm's stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $66,711.33. Following the sale, the chief financial officer now owns 143,242 shares of the company's stock, valued at $3,227,242.26. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Benjamin J. Hindson sold 4,351 shares of the business's stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $98,028.03. Following the transaction, the insider now directly owns 345,704 shares of the company's stock, valued at $7,788,711.12. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,061 shares of company stock worth $316,794 in the last quarter. 10.03% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on TXG shares. Jefferies Financial Group upgraded shares of 10x Genomics from a "hold" rating to a "buy" rating and set a $24.00 price target on the stock in a report on Monday, July 22nd. The Goldman Sachs Group reduced their target price on 10x Genomics from $26.00 to $16.00 and set a "sell" rating for the company in a report on Tuesday, July 9th. Leerink Partnrs upgraded 10x Genomics to a "strong-buy" rating in a report on Tuesday, September 3rd. Stifel Nicolaus reduced their price objective on 10x Genomics from $53.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 16th. Finally, Morgan Stanley lowered their target price on 10x Genomics from $50.00 to $46.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $30.60.

10x Genomics Stock Up 2.5 %

TXG traded up $0.37 on Thursday, hitting $15.47. The company's stock had a trading volume of 1,590,007 shares, compared to its average volume of 1,697,025. 10x Genomics, Inc. has a 12 month low of $14.02 and a 12 month high of $57.90. The firm has a market cap of $1.86 billion, a P/E ratio of -7.66 and a beta of 1.85. The company's 50 day simple moving average is $20.78 and its 200-day simple moving average is $22.19.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.15. 10x Genomics had a negative return on equity of 28.23% and a negative net margin of 37.90%. The firm had revenue of $153.10 million during the quarter, compared to analyst estimates of $150.90 million. Equities analysts predict that 10x Genomics, Inc. will post -1.35 earnings per share for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.